At least 1 month should elapse between a dose of M-M-R II and a dose of ProQuad. If for any reason a second dose of varicella-containing vaccine is required, at least 1 month should elapse between administration of the 2 doses.
Administration of immune globulins (IG) concomitantly with ProQuad may interfere with the expected immune response. Vaccination should be deferred for at least 3 months following blood or plasma transfusions, or administration of IG. However, the appropriate suggested interval between transfusion or IG administration and vaccination will vary with the type of transfusion or indication for, and dose of, IG (e.g., 5 months for VZIG).
Following administration of ProQuad, any IG including VZIG should not be given for 1 month thereafter unless its use outweighs the benefits of vaccination.
Vaccine recipients should avoid use of salicylates for 6 weeks after vaccination with ProQuad as Reye syndrome has been reported following the use of salicylates during wild-type varicella infection.
The fourth dose of DTaP (diphtheria, tetanus, acellular pertussis vaccine) is indicated for children 15 months of age and older. Limited data suggest that ProQuad may be administered concomitantly (at separate injection sites) with DTaP in children 15 months of age and older.
Results from clinical studies indicate that ProQuad may be administered concomitantly with Haemophilus b conjugate (meningococcal protein conjugate), hepatitis B (recombinant), pneumococcal conjugate, and hepatitis A (inactivated) vaccines.
There are no data for the administration of ProQuad with inactivated poliovirus vaccine.